zdorПроблемы здоровья и экологииHealth and Ecology Issues2220-09672708-6011Gomel State Medical University10.51523/2708-6011.2023-20-2-02zdor-2544Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESНеоадъювантная полихимиотерапия в комплексном лечении рака желудкаNeoadjuvant polychemotherapy in the complex treatment of gastric cancerhttps://orcid.org/0000-0003-4682-2045ДятловА. П.DyatlovA. P.

Дятлов Александр Петрович, ассистент кафедры онкологии;

врач онколог-хирург онкологического абдоминального отделения

Гомель

Alexandr P. Dyatlov, Assistant at the Department of Oncology;

Oncologist-Surgeon of the Oncologic Abdominal Department

Gomel

dyatlov-ap@mail.ruhttps://orcid.org/0000-0002-3796-0342МихайловИ. В.MikhailovI. V.

Михайлов Игорь Викторович, к.м.н., доцент,  заведующий кафедрой онкологии

Гомель

Igor V. Mikhailov, PhD (Med), Head of the Department of Oncology

Gomel

igor-mikhailov-2014@yandex.ruhttps://orcid.org/0000-0002-1512-8539КудряшовВ. А.KudrashouV. A.

Кудряшов Вадим Андреевич, заведующий онкологическим абдоминальным отделением

Гомель

Vadzim A. Kudrashou, Head of the Abdominal OncologyDepartment

Gomel

vadimkudryashov@tut.byГомельский государственный медицинский университет; Гомельский областной клинический онкологический диспансерGomel State Medical University; Gomel Regional Clinical Oncology CenterГомельский государственный медицинский университетGomel State Medical UniversityГомельский областной клинический онкологический диспансерGomel Regional Clinical Oncology Center2023100720232021421Copyright © Дятлов А.П., Михайлов И.В., Кудряшов В.А., 20232023Дятлов А.П., Михайлов И.В., Кудряшов В.А.Dyatlov A.P., Mikhailov I.V., Kudrashou V.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.gsmu.by/jour/article/view/2544

Цель исследования. Проанализировать и систематизировать данные о применении неоадъювантной химиотерапии в комплексном лечении рака желудка.Материалы и методы. Изучены оригинальные публикации, содержащие информацию о применении неоадъювантной химиотерапии в комплексном лечении рака желудка, депонированные в ресурсах PubMed и информационного портала eLIBRARY.RU.Результаты. Выделены наиболее важные аспекты, касающиеся применения неоадъювантной полихимиотерапии в комплексном лечении рака желудка.Заключение. Согласно имеющимся литературным данным, применение неоадъювантной химиотерапии может послужить важным фактором предупреждения прогрессирования опухолевого процесса за счет воздействия на невыявленные микрометастазы, однако многие аспекты в научных публикациях освещены недостаточно. Поэтому изучение применения неоадъювантной химиотерапии в комплексном лечении рака желудка, включающем лимфодиссекцию в объеме D2, является в настоящее время весьма актуальным.

Objective. To analyze and systematize data on the use of neoadjuvant chemotherapy in the complex treatment of stomach cancer.Materials and methods. The original publications containing information on the use of neoadjuvant chemotherapy in the complex treatment of gastric cancer deposited in the resources of PubMed and the information portal eLIBRARY.RU have been studied.Results. The most important aspects concerning the use of neoadjuvant polychemotherapy in the complex treatment of gastric cancer have been outlined.Conclusion. According to the available literature data, the use of neoadjuvant chemotherapy can serve as an important factor in preventing the progression of the tumor process due to the impact on undetected micrometastases, but many aspects are not covered sufficiently in scientific publications. Therefore, the study of neoadjuvant chemotherapy in the complex treatment of gastric cancer, including D2 lymphodissection, is currently very relevant.

рак желудканеоадъювантная полихимиотерапияадъювантная полихимиотерапиялимфодиссекцияstomach cancerneoadjuvant polychemotherapyadjuvant polychemotherapylymphadenectomyReferencesЛядов В.К., Пардабекова О.А., Лядова М.А. Периоперационная химиотерапия рака желудка: состояние проблемы. Современная онкология. 2018;20(2):56-60. DOI: https://doi.org/10.26442/1815-1434_2018.2.56-60Lyadov VK, Pardabekova O A, Lyadova MA. Perioperative chemotherapy for stomach cancer: the state of the problem. Modern oncology. 2018;20(2):56-60. (In Russ.). DOI: https://doi.org/10.26442/1815-1434_2018.2.56-60Афанасьев С.Г., Августинович А.В., Давыдов И.М., Волков М.Ю. Неоадъювантная химиотерапия при комбинированном лечении рака желудка. Онкология. 2014;3(6):13-18. DOI: https://doi.org/10.17116/oncolog2014613-18Afanasyev SG, Augustinovich AV, Davydov IM, Volkov MU. Neoadjuvant chemotherapy in the combined treatment of gastric cancer. Oncology. 2014;3(6):13-18. (In Russ.) DOI: https://doi.org/10.17116/oncolog2014613-18Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer 15-year followup results of the randomized nationwide Dutch D1D2 trial. LancetOncol.2010;11(4):39-49. DOI: https://doi.org/10.1016/S1470-2045(10)70070-XSongun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer 15-year followup results of the randomized nationwide Dutch D1D2 trial. LancetOncol.2010;11(4):39-49. DOI: https://doi.org/10.1016/S1470-2045(10)70070-XДавыдов М.И., Тер-Ованесов М.Д., Абдихакимов А.Н., Марчук В.А. Рак желудка: что определяет стандарты хирургического лечения. В: Тюляндин С.А., Моисеенко В.М., ред. Практическая онкология: избранные лекции. Санкт-Петербург; 2004. с. 473-483.Davydov MI, Ter-Ovanesov MD, Abdihakimov A N, Marchuk V A. Gastric cancer: what determines the standards of surgical treatment. In: Tyulyandin SA, Moiseenko V M, ed. Practical oncology: selected lectures. St. Petersburg; 2004. P. 473-483. (In Russ.).Fujitani K. Overview of adjuvant and neoadjuvant therapy for resectable gastric cancer in the East. Digestive surgery. 2013;30(2):119-129. DOI: https://doi.org/10.1159/000350877Fujitani K. Overview of adjuvant and neoadjuvant therapy for resectable gastric cancer in the East. Digestive surgery. 2013;30(2):119-129. DOI: https://doi.org/10.1159/000350877Schirren R, Reim D, Novotny AR. Adjuvant and/or neoadjuvant therapy for gastric cancer? A perspective review. Ther Adv Med Oncol. 2015;7(1):39-48. DOI: https://doi.org/10.1177/1758834014558839Schirren R, Reim D, Novotny AR. Adjuvant and/or neoadjuvant therapy for gastric cancer? A perspective review. Ther Adv Med Oncol. 2015;7(1):39-48. DOI: https://doi.org/10.1177/1758834014558839Reddavid R, Sofia S, Chiaro P, Colli F, Trapani R, Esposito L, et al. Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake? World journal of gastroenterology. 2018;24(2):274-289. DOI: https://doi.org/10.3748/wjg.v24.i2.274Reddavid R, Sofia S, Chiaro P, Colli F, Trapani R, Esposito L, et al. Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake? World journal of gastroenterology. 2018;24(2):274-289. DOI: https://doi.org/10.3748/wjg.v24.i2.274Shigeyuki T, Atsushi T, Hirofumi M. Lymph Node Dissection in Curative Gastrectomy for Advanced Gastric Cancer. International Journal of Surgical Oncology. 2011:748745. DOI: https://doi.org/10.1155/2011/748745Shigeyuki T, Atsushi T, Hirofumi M. Lymph Node Dissection in Curative Gastrectomy for Advanced Gastric Cancer. International Journal of Surgical Oncology. 2011:748745. DOI: https://doi.org/10.1155/2011/748745Карачун АМ, Беляев АМ, Синенченко ГИ, Пелипась ЮВ. Объем лимфодиссекции при раке желудка: общепринятый стандарт или предмет для дискуссий (обзор литературы). Сибирский онкологический журнал. 2011;47(5):70-78. DOI: https://doi.org/616.33-006.6:611.428]-089Karachunam, Belyaeva M, Sinenchenko G I, Pelipas Yu V. The volume of lymph dissection in gastric cancer: a generally accepted standard or a subject for discussion (literature review). Siberian Journal of Oncology. 2011;5(47):70-78. (In Russ.) DOI: https://doi.org/616.33-006.6:611.428]-089Lavy R, Hershkovitz Y, Chikman B, Shapira Z, Poluksht N, Yarom N, et al. D1 versus D2 Gastrectomy for Gastric Adenocarcinoma. Israel Medical Association Journal. 2015;17(12):735-738. [date of access 2023 May 10]. Available from: https://pubmed.ncbi.nlm.nih.gov/26897973Lavy R, Hershkovitz Y, Chikman B, Shapira Z, Poluksht N, Yarom N, et al. D1 versus D2 Gastrectomy for Gastric Adenocarcinoma. Israel Medical Association Journal. 2015;17(12):735-738. [date of access 2023 May 10]. Available from: https://pubmed.ncbi.nlm.nih.gov/26897973Younis M, Yousuf A, Ahmad SN, Vane A. Comparison of D2 versus D1 gastrectomy in Kashmiri patients in a tertiary care cancer centre. International Surgery Journal. 2022;9(3):552-558. DOI: https://doi.org/10.18203/2349-2902.isj20220363Younis M, Yousuf A, Ahmad SN, Vane A. Comparison of D2 versus D1 gastrectomy in Kashmiri patients in a tertiary care cancer centre. International Surgery Journal. 2022;9(3):552-558. DOI: https://doi.org/10.18203/2349-2902.isj20220363Leong T, Smithers BM, Haustermans K, Michael M, Gebski V, Miller D, et al. TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG. Ann SurgOncol. 2017;24(8):2252-2258. DOI: https://doi.org/10.1245/s10434-017-5830-6Leong T, Smithers BM, Haustermans K, Michael M, Gebski V, Miller D, et al. TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG. Ann SurgOncol. 2017;24(8):2252-2258. DOI: https://doi.org/10.1245/s10434-017-5830-6Tomasello G, Petrelli F, Ghidini M, Pezzica E, Passalacqua R, Steccanella F, et al. Tumor regression gradeand survival after neoadjuvant treatment in gastro-esophageal cancer: Ameta-analysis of 17 published studies. Eur J SurgOncol. 2017;43(9):1607-1616. DOI: https://doi.org/10.1016/j.ejso.2017.03.001Tomasello G, Petrelli F, Ghidini M, Pezzica E, Passalacqua R, Steccanella F, et al. Tumor regression gradeand survival after neoadjuvant treatment in gastro-esophageal cancer: Ameta-analysis of 17 published studies. Eur J SurgOncol. 2017;43(9):1607-1616. DOI: https://doi.org/10.1016/j.ejso.2017.03.001Trip AK, Poppema BJ, van Berge Henegouwen MI, Siemerink E, Beukema JC, Verheij M, et al. Preoperative chemoradiotherapyin locally advanced gastric cancer, a phase I/II feasibility andefficacy study. RadiotherOncol. 2014;112(2):284-288. DOI: https://doi.org/10.1016/j.radonc.2014.05.003Trip AK, Poppema BJ, van Berge Henegouwen MI, Siemerink E, Beukema JC, Verheij M, et al. Preoperative chemoradiotherapyin locally advanced gastric cancer, a phase I/II feasibility andefficacy study. RadiotherOncol. 2014;112(2):284-288. DOI: https://doi.org/10.1016/j.radonc.2014.05.003Скоропад В.Ю., Афанасьев С.Г., Гамаюнов С.В., Силантьева Н.К., Агабабян Т.А., Соколов П.В. и др. Многоцентровое рандомизированное клиническое исследование 2 фазы: неоадъювантная химиолучевая терапия с последующей гастрэктомией D2 и адъювантной химиотерапией у больных местнораспространенным раком желудка. Сибирский онкологический журнал. 2020;19(1):5-14. DOI: https://doi.org/10.21294/1814-4861-2020-19-1-5-14Skoropad V Yu, Afanasyev S G, Gamayunov S V, Silantieva NK, Aghababyan TA, Sokolov P V, et al. Multicenter randomized phase 2 clinical trial: neoadjuvant chemoradiotherapy followed by D2 gastrectomy and adjuvant chemotherapy in patients with locally advanced gastric cancer. Siberian Journal of Oncology. 2020;19(1):5-14. (In Russ.). DOI: https://doi.org/10.21294/1814-4861-2020-19-1-5-14Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. The Lancet. Oncology. 2016;17(12):1697-1708. DOI: https://doi.org/10.1016/S1470-2045(16)30531-9Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. The Lancet. Oncology. 2016;17(12):1697-1708. DOI: https://doi.org/10.1016/S1470-2045(16)30531-9Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948-1957. DOI: https://doi.org/10.1016/S0140-6736(18)32557-1Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948-1957. DOI: https://doi.org/10.1016/S0140-6736(18)32557-1Бесова Н.С., Болотина Л.В., Калинин А.Е., Кононец П.В., Малихова О.А., Проценко С.А. и др. Практические рекомендации по лекарственному лечению рака желудка. Злокачественные опухоли. 2019;9(3S2):308-323. DOI: https://doi.org/10.18027/2224-5057-2019-9-3s2-308-323Besova NS, Bolotina LV, Kalinin AE, Kononets PV, Melikhova OA, Protsenko SA, et al. Practical recommendations for the drug treatment of stomach cancer. Malignant tumors. 2019;9(3S2):308-323. (in Russ.). DOI: https://doi.org/10.18027/2224-5057-2019-9-3s2-308-323Августинович А.В., Афанасьев С.Г., Добродеев А.Ю., Волков М.Ю., Костромицкий Д.Н., Спирина Л.В. и др. Непосредственная эффективность и токсичность тотальной неоадъювантной химиотерапии резектабельного рака желудка. Сибирский онкологический журнал. 2022;21(1):11-19. DOI: https://doi.org/10.21294/1814-4861-2022-21-1-11-19Augustinovich AF, Afanasyev S G, DobrodeevA Yu, Volkov MU, Kostromitsky DN, Spirina LV, et al. Immediate efficacy and toxicity of total neoadjuvant chemotherapy for resectable stomach cancer. Siberian Journal of Oncology. 2022;21(1):11-19. (In Russ.). DOI: https://doi.org/10.21294/1814-4861-2022-21-1-11-19Erdem GU, Bozkaya Y, Ozdemir NY, Demirci NS, Yazici O, Zengin N. 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as a third-line chemotherapy treatment in metastatic gastric cancer, after failure of fluoropyrimidine, platinum, anthracycline, and taxane. Bosnian journal of basic medical sciences. 2016;18(2):170-177. DOI: https://doi.org/10.17305/bjbms.2017.2258Erdem GU, Bozkaya Y, Ozdemir NY, Demirci NS, Yazici O, Zengin N. 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as a third-line chemotherapy treatment in metastatic gastric cancer, after failure of fluoropyrimidine, platinum, anthracycline, and taxane. Bosnian journal of basic medical sciences. 2016;18(2):170-177. DOI: https://doi.org/10.17305/bjbms.2017.2258Maugeri-Saccà M, Pizzuti L, Sergi D, Barba M, Belli F, Fattoruso S, et al. FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort. J ExpClin Cancer Res. 2013 Sep 17;32(1):67. DOI: https://doi.org/10.1186/1756-9966-32-67Maugeri-Saccà M, Pizzuti L, Sergi D, Barba M, Belli F, Fattoruso S, et al. FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort. J ExpClin Cancer Res. 2013 Sep 17;32(1):67. DOI: https://doi.org/10.1186/1756-9966-32-67Nguyen HV, Nguyen HV, Nguyen LT, Pham NQ, Nguyen HX, Nguyen HX, et al. A Case of Advanced Gastric Cancer with Folfiri as a Preoperative Chemotherapy. Case reports in oncological medicine. 2019 Nov 29:1352173. DOI: https://doi.org/10.1155/2019/1352173Nguyen HV, Nguyen HV, Nguyen LT, Pham NQ, Nguyen HX, Nguyen HX, et al. A Case of Advanced Gastric Cancer with Folfiri as a Preoperative Chemotherapy. Case reports in oncological medicine. 2019 Nov 29:1352173. DOI: https://doi.org/10.1155/2019/1352173Dank M, Zaluski J, Barone C, Valvere V, Yalcin S, Peschel C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Annals of Oncology. 2008;19(8):1450-1457. DOI: https://doi.org/10.1093/annonc/mdn166Dank M, Zaluski J, Barone C, Valvere V, Yalcin S, Peschel C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Annals of Oncology. 2008;19(8):1450-1457. DOI: https://doi.org/10.1093/annonc/mdn166Трусилова Е.В., Бесова Н.С., Горбунова В.А., Бондаренко Ю.В. Эффективность и токсичность химиотерапии по схеме FOLFIRINOX у больных диссеминированным раком желудка. Предварительные результаты. Эффективная фармакотерапия. 2013;4(46):6-13. [дата обращения 2023 май 10]. Режим доступа: https://umedp.ru/upload/iblock/f77/f7718c31025af1430c9a9127f5202e4a.pdfTrusilova EV, Besova NS, Gorbunova VA, Bondarenko YuV. Efficacy and toxicity of FOLFIRINOX chemotherapy in patients with disseminated gastric cancer. Preliminary results. Effective pharmacotherapy. 2013;4(46):6-13. [date of access 2022 May 10]. Available from: https://umedp.ru/upload/iblock/f77/f7718c31-025af1430c9a9127f5202e4a.pdf (In Russ.).Cao W, Yang W, Lou G, Jiang J, Geng M, Xi W, et al. Phase II trial of infusionalfluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer. Anticancer Drugs. 2009;20(4):287-293. DOI: https://doi.org/10.1097/CAD.0b013e3283273509Cao W, Yang W, Lou G, Jiang J, Geng M, Xi W, et al. Phase II trial of infusionalfluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer. Anticancer Drugs. 2009;20(4):287-293. DOI: https://doi.org/10.1097/CAD.0b013e3283273509Lee J, Kang WK, Kwon JM, Oh SY, Lee HR, Kim HJ, et al. Phase II trial of irinotecanplus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma. Annals of Oncology. 2007;18(1):88-92. DOI: https://doi.org/10.1093/annonc/mdl317Lee J, Kang WK, Kwon JM, Oh SY, Lee HR, Kim HJ, et al. Phase II trial of irinotecanplus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma. Annals of Oncology. 2007;18(1):88-92. DOI: https://doi.org/10.1093/annonc/mdl317Wo JY, Clark JW, Eyler CE, Mino-Kenudson M,Klempner SJ, Allen JN, et al. Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas. Clinical cancer research: an official journal of the American Association for Cancer Research. 2021;27(23):6343-6353. DOI: https://doi.org/10.1158/1078-0432.CCR-21-0331Wo JY, Clark JW, Eyler CE, Mino-Kenudson M,Klempner SJ, Allen JN, et al. Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas. Clinical cancer research: an official journal of the American Association for Cancer Research. 2021;27(23):6343-6353. DOI: https://doi.org/10.1158/1078-0432.CCR-21-0331

The authors declare that there are no conflicts of interest present.